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ABSTRACT
Objective: To estimate the incidence and distribution of the degree of radiodermatitis 
in cancer patients submitted to radiotherapy in the regions of head and neck, breast, 
and pelvis. Method: Prospective, longitudinal, quantitative study conducted from 
March 15, 2016 to May 4, 2017 with patients observed for five weeks of treatment. The 
primary outcome was the proportion of grade 1 or higher radiodermatitis each week. The 
degree of radiodermatitis and mean time of occurrence for each patient were secondary 
outcomes. Results: This study included 112 patients. The incidence of radiodermatitis 
was 100% among those whose head and neck region was irradiated, followed by 98% 
for breast and 48% for the pelvic region. The degree of radiodermatitis varied with the 
irradiated site; the worst degrees were found in the head and neck region, followed by the 
breast. In the three groups, the mean time of the first occurrence of radiodermatitis was 
approximately eleven days. Conclusion: The incidence of radiodermatitis in the studied 
groups was high, which reinforces the need to perform the same evaluation nationwide. 
This would support creating and standardizing protocols and recommendations for a 
proper management of radiodermatitis, specially concerning its prevention.
DESCRIPTORS
Radiodermatitis; Head and Neck Neoplasms; Breast Neoplasms; Pelvic Neoplasms; 
Oncology Nursing.
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INTRODUCTION
Radiodermatitis is a cutaneous reaction to ionizing radia-
tion exposure which varies from mild erythema to severer 
reactions, such as dry or moist desquamation. This reaction 
is commonly reported by the international literature to afflict 
cancer patients who undergo irradiation of the regions of 
head and neck, breast, and pelvis, whose skin is part of the 
target irradiation area(1-2). However, the incidence of this 
reaction in Brazil is unknown.
The pathogenesis of radiodermatitis results from cell 
damage due to ionizing radiation exposure followed by an 
inflammatory response which affects skin layers (epidermis, 
dermis, and hypodermis or subcutaneous tissue)(2). Such cell 
damage takes place direct or indirectly by the formation of 
reactive oxygen species and impacts essentially the capacity 
of cell division and multiplication(3-4). Actively proliferating 
cells are thus, similarly to the basal cells constituting the 
epidermis, more radiosensitive(2).
The skin presents a balanced system of cell production 
and destruction in the epidermis (basal layer). This balance 
is broken after the first radiotherapy session, when kerati-
nocyte destruction starts. With subsequent radiotherapy 
sessions, there is an accumulation of dose, increasing unbal-
ance, which predisposes to changes to epidermis integrity 
and skin healing processes. Such changes surface with the 
appearance of erythema, xerosis, desquamation, itching, and 
hyperpigmentation(1,5).
Erythema develops from a response to damage to the skin 
basal layer and as a consequence of an inflammatory process 
which initiates with histamine release and hypervascularity. It 
occurs around 10 to 14 days after radiotherapy(1,6) in patients 
receiving doses between 6 and 20 Gy and may be associated 
to symptoms such as discomfort, itching, and xerosis(6). 
After three to four weeks of treatment, as a compensa-
tory response, mitotic activity is increased and stimulates the 
migration of new cells to substitute the damaged ones. The 
new cells are produced faster than the old ones are eliminated, 
originating dry desquamation, common in doses higher than 
20 Gy. Continuous exposure to radiotherapy decreases the 
capacity of the basal layer to efficiently produce new cells to 
substitute damaged cells, which results in epidermal detach-
ment, release of serous fluid and formation of wet blisters, 
covering a partial or confluent area of the treated region. 
This reaction is called moist desquamation and may surface 
after doses higher than 30 Gy(6).
The development of radiodermatitis and its severity are 
related to extrinsic and intrinsic factors. Extrinsic factors 
include the treatment (total dose, volume of irradiated area, 
fractionation, and planning technique) and intrinsic factors 
refer to the patient (age, genetic antecedents, molecular sub-
types, size and shape of the irradiated area)(7-9).
Acute radiodermatitis in severer degrees may limit the 
therapeutic dose of radiation(10), contribute to delayed com-
pletion or even interruption of radiotherapy, causing a nega-
tive impact on therapy success(1,11-12). Also, radiodermatitis 
is responsible for aesthetic alterations, discomfort, pain, and 
reduced patient quality of life(12).
The available literature presents a gap concerning the 
incidence of radiodermatitis in Brazil and, although the phys-
iopathology of radiodermatitis is known, studies presenting 
the distribution of the degree of radiodermatitis throughout 
treatment for each irradiated area are also required. Obtaining 
this data may contribute to establishing common grounds 
and recommendations for managing radiodermatitis. This 
study’s objective was thus verifying the incidence of radio-
dermatitis in cancer patients submitted to radiotherapy in 
the regions of head and neck, breast, and pelvis.
METHOD
Study deSign
Prospective, longitudinal, quantitative study. 
Scenario
A radiotherapy outpatient clinic of a High Complexity 
Oncology Unit (Unidade de Alta Complexidade em Oncologia 
– UNACON) of the University Hospital of Brasília (Hospital 
Universitário de Brasília – HUB), associated to Universidade 
de Brasília (UnB). 
Selection criteria
The sample comprised all patients with cancer in the 
regions of head and neck, breast, or pelvis (prostate, cervix, 
and endometrium) submitted to radiotherapy from March 
15, 2016 to May 4, 2017 who agreed to participate in the 
study. The patients were treated in a radiotherapy device of 
the type Linear Accelerator manufactured by VARIAN, 
model CLINAC CX, employing a three-dimensional con-
formal (3D – CRT) planning. 
The inclusion criteria were patients aged 18 or older 
with an indication to start radiotherapy for treatment of 
head and neck, breast, or pelvis (prostate, cervix, and endo-
metrium) cancer in any clinical stage. The exclusion criteria 
were: patients with an indication of urgent radiotherapy 
due to tumor complications (superior vena cava syndrome, 
medullary compression syndrome, intracranial hypertension 
syndrome, and hemorrhage), patients with tumor wounds in 
the treatment region which could interfere with the evalua-
tion of radiodermatitis, and patients with a record of radio-
therapy of the evaluated region. 
data collection
The participants were recruited during the nursing con-
sultation carried out in the first day of radiotherapy in the 
outpatient unit of UNACON/HUB. After receiving infor-
mation about the necessary cautions during radiotherapy 
according to the routine of the nursing outpatient unit, the 
patients were invited to participate in the study. After receiv-
ing the necessary information about the research during the 
nursing consultation and agreeing to participate, the patients 
signed the Informed Consent Form (ICF).
General recommendations of care with irradiated skin area 
include cleaning the skin with mild soap, hydrating the skin 
with water-based creams, photoprotection, and avoiding skin 
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friction(13). Also, for each degree of radiodermatitis, specific 
topical products were indicated, namely: chamomile gel (used 
in a prophylactic way when patients have intact skin and in 
case of erythema), chamomile tea compress in case of dry des-
quamation, and silver sulfadiazine for moist desquamation(13). 
In this first consultation, patients’ sociodemographic and 
clinical data were collected, in addition to a skin evaluation 
abiding by the radiodermatitis classification criteria of the 
Oncology Nursing Society (ONS)(14). Also, a photograph of 
their skin was taken with a Nikon – Coolpix P510 digital 
camera, excluding patients who had pelvic tumors, since 
this is an intimate area. For such patients, evaluation was 
performed through visual inspection of the treatment area 
by the nurse. The classification proposed by ONS(14) was 
employed to measure the degree of radiodermatitis: (0) no 
change, (1.0) faint or dull erythema, (1.5) bright erythema, 
(2.0) dry desquamation with or without erythema, (2.5) 
small to moderate amount of moist desquamation, (3.0) 
confluent moist desquamation, and (3.5) ulceration, hemor-
rhage, or necrosis.
The sociodemographic and clinical characteristics col-
lected were: age (in years), gender (feminine or masculine), 
self-reported color (white, brown or black), educational level 
(illiterate, primary, secondary, or superior), smoking status 
(smoker, former smoker or never smoked), drinking status 
(drinker, former drinker or never drank), presence of diabe-
tes, daily sun exposure, Performance Status, tumor location, 
current treatment (chemotherapy, radiotherapy or chemo-
radiotherapy), type of energy, and total dose (Gy). Also, for 
participants with breast cancer, Body Mass Index (BMI) was 
collected and transformed into the following classification: 
Obese (BMI ≥ 30 kg/m2), Overweight (BMI > 25 and < 
29.9 Kg/m2), Normal Weight (BMI >18.5 and < 24.9 Kg/
m2) and Underweight (BMI < 18.5 Kg/m2), as well as bra 
size (Brazilian sizes: 42, 44, 46, 48, 50). All these variables 
were registered in a self-created instrument.
The nurse researcher evaluated the participants every 
week during the treatment, following the ONS criteria(14) 
for assessing skin integrity, occurrence of radiodermatitis, 
and photographic register (except pelvis). The patients were 
followed up during the phase 1 of the treatment (five weeks) 
since some of them had to wait for further therapeutic plan-
ning to proceed to subsequent treatment phases and radio-
dermatitis assessment would not be continuous.
data treatment and analySiS
The sociodemographic and clinical characteristics were 
presented in a descriptive manner.
The primary outcome was the presence of radiodermatitis, 
defined as the emergence of grade 1 or higher radiodermatitis 
during the treatment weeks. Each week, the proportion of 
patients presenting radiodermatitis was calculated and the 
estimate and 95% confidence interval were calculated by 
Bayesian method (using Jeffreys prior). 
Concerning the secondary outcomes, the distribution 
of the degree of radiodermatitis by week was presented in a 
descriptive manner and the means, medians, standard devia-
tion and extreme values of the time in days until the first 
observation of radiodermatitis within each group (head and 
neck, breast, and pelvis) were calculated. 
 The analyses of mean and frequency were carried out 
using SPSS version 25 for Mac, and the confidence interval 
for proportions and graphs was calculated with the soft-
ware RStudio.
ethical aSpectS
The research project was approved by the Research 
Ethics Committee of the Health Sciences Faculty of UnB 
in Opinion 610.425, dated 2013, following the recommenda-
tions of Resolution 466/12 by the National Health Council 
concerning research with human subjects. All participants 
have signed the Informed Consent Form. 
RESULTS
Out of 163 evaluated patients, 50 were non-eligible (30 
presented tumor wounds in the irradiated region and 20 had 
received urgent radiotherapy). Among eligible patients, one 
refused participation and 112 were included (31 with head 
and neck cancer, 50 with breast cancer, and 31 with cancer 
in the pelvis region). There was no loss to follow-up during 
the assessment period. 
Clinical and sociodemographic characterization of par-
ticipants is presented in Table 1. The mean age of patients 
with head and neck cancer was 58.8 years (standard devia-
tion [SD] =14.5 years); 68% were male and 68% were white. 
The predominant tumor site was the oral cavity, identified 
in 13 (42%) patients. Regarding the current treatment, 21 
(68%) were undergoing chemoradiotherapy and 10 (32%) 
were undergoing exclusive radiotherapy. The treatment was 
conducted in a mean of 25 sessions, with a total dose of 50 
Gy; the type of energy used was photons. 
The mean age of participants with breast cancer was 53 
years (SD = 13.4). The most frequent histological type in the 
sample was Invasive Ductal Carcinoma (94%). Most partici-
pants were above the recommended weight: 40% were obese 
and 36% were overweight (Table 1). Among participants who 
preserved their breast or underwent breast reconstruction, 
16 (32%) wore bras of a size between 42 and 46, 5 (10%) 
used size 48, and 5 (10%) used a size higher than 50. Fifteen 
patients (30%) were receiving exclusive radiotherapy and 35 
(70%), radiotherapy concomitant to another therapy (trastu-
zumab or hormone therapy). Hypofractionated radiation, in 
which there is a reduction in the total number of fractions 
and increase in the administered daily dose, was conducted 
in 9 patients (18%). The mean total radiotherapy dose was 
48 Gy and the most employed type of energy was photons.
The mean age of patients who received pelvic radio-
therapy was 62.4 years (SD = 11). Most (74%) had prostate 
cancer, followed by cervix cancer (16%) and endometrium 
cancer (10%). Seventeen patients (55%) were submitted to 
radiotherapy concomitantly to hormone therapy, 7 (23%) 
to chemoradiotherapy and seven (23%) to exclusive radio-
therapy. The mean total dose was 49 Gy (cervix), 50 Gy 
(endometrium), and 54 Gy (prostate).
4 www.scielo.br/reeusp
Acute radiodermatitis in cancer patients: incidence and severity estimates
Rev Esc Enferm USP · 2021;55:e03676
Table 1 – Sociodemographic and clinical characteristics of pa-
tients treated in the service between March 2016 and May 2017 
– Brasília, DF, Brazil, 2018. 
Sociodemographic and Clinical 
Characteristics
HN Breast Pelvis 
(n = 
31) (n = 50) (n=31)














Male 21 (68) 1 (2) 23 (74)
Female 10 (32) 49 (98) 8 (26)
BMI categories, n (%)
Obese (BMI ≥ 30 kg/m2) - 20 (40) -
Overweight (BMI > 25 and < 
29.9 Kg/m2) - 18 (36) -
Normal Weight (BMI >18.5 and 
< 24.9 Kg/m2) - 11 (22) -
Underweight (BMI < 18.5 Kg/
m2) - 1 (2) -
Color
White 21 (68) 21 (42) 10 (32)
Brown 9 (29) 24 (48) 5 (16)
Black 1 (3) 5 (10) 16 (52)
Educational level
Illiterate 2 (6) 4 (8) 2 (7)
Primary 19 (62) 14 (28) 16 (52)
Secondary 9 (27) 27 (54) 9 (29)
Superior 1 (3) 5 (10) 4 (13)
Smoking status
Smoker 2 (6) 4 (8) 5 (16)
Former smoker 25 (81) 16 (32) 14 (45)
Never smoked 4 (13) 30 (60) 12 (39)
Drinking status
Drinker 3 (10) 17 (34) 12 (39)
Former drinker 23 (74) 2 (4) 10 (32)
Never drank 5 (16) 31 (62) 9 (29)
Presence of diabetes, n (%) 5 (16) 10 (20) 6 (19)
Daily sun exposure, yes, n (%) 24 (77) 0 (0) 4 (13)
Performance Status (PS)
Normal activity (PS 0) 29 (94) 43 (86) 28 (90)
Presence of disease symptoms, 
but able to ambulate and lead a 
normal routine (PS 1)
2 (6) 7 (14) 3 (10)
radiodermatitiS in patientS receiving radiotherapy 
in the region of head and neck
Table 2 presents the results for the occurrence and degree 
of radiodermatitis throughout time for patients whose region 
of head and neck was irradiated. All participants presented 
some degree of radiodermatitis during the treatment, with 
a mean time for first event occurrence of eleven days (SD = 
5.4; median =10 [min = 5, max = 30]). In the first week of 
treatment (W1), 35% presented erythema, which increased 
to 68% in the second week (W2) and 87% in the third 
week (W3), out of which 7% evolved to dry desquamation. 
From the fourth week onwards, the proportion of individuals 
with erythema decreased, but there was an increase in dry 
desquamation (33%) and evolution to moist desquamation 
of a subject on week 4 and two on week 5.
Table 2 – Number of participants with head and neck cancer by 
occurrence and degree of radiodermatitis in each treatment 
week – Brasília, DF, Brazil, 2018.
Degree of 
Radiodermatitis
Number of patients with radiodermatitis
W1 W2 W3 W4 W5
n 31 31 31 31 31
0 No change 20 10 2 1 2
1 Faint or dull erythema 10 19 13 4 0
1.5 Bright erythema 1 2 14 15 8
2
Dry desquamation 
with or without 
erythema
0 0 2 10 19
2.5
Small to moderate 
amount of moist 
desquamation
0 0 0 1 1
3 Confluent moist desquamation 0 0 0 0 1
Proportion of patients 



















occurrence of radiodermatitiS in the breaSt region
Among participants irradiated in the breast region, 98% 
acquired radiodermatitis during the treatment, with a mean 
time for first occurrence of radiodermatitis of eleven days 
(SD = 3.7). Erythema was the predominant sign among 
patients; it was present in all five weeks of follow-up, espe-
cially in weeks 3 and 4 (Table 3). Dry desquamation occurred 
in Weeks 4 (W4) and 5 (W5), with 6% and 10%, respec-
tively. Moist desquamation started in Week 3 (W3), with an 
increased frequency in subsequent weeks. No patient pre-
sented ulcer, hemorrhage, or necrosis during the treatment. 
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Table 3 – Proportion of participants whose breast was irradiated 
by occurrence and degree of radiodermatitis in each treatment 




W1 W2 W3 W4 W5
n 50 50 48 43 32
0 No change 42 17 5 1 1
1 Faint or dull erythema 8 30 29 14 4
1.5 Bright erythema 0 3 12 18 11
2
Dry desquamation 
with or without 
erythema
0 0 0 6 10
2.5
Small to moderate 
amount of moist 
desquamation
0 0 1 4 6
3 Confluent moist desquamation 0 0 1 0 0
Proportion of patients 






















occurrence of radiodermatitiS in the pelvic region
Among patients with cervix cancer, four presented some 
degree of radiodermatitis, with a mean occurrence time of 7 
days (SD = 4.8). Among patients with endometrium cancer, 
only one presented radiodermatitis during the treatment, 
with an occurrence time of 11 days; among patients with 
prostate cancer, twelve presented radiodermatitis during 
the treatment and the mean time of occurrence was 18 days 
(SD=13), which was late when compared to the other regions. 
Among patients whose pelvic region was irradiated, com-
pared to the regions of head and neck and breast, there was 
a smaller occurrence of radiodermatitis (48.4%). However, 
the occurrence of moist desquamation during all the weeks 
of evaluation (Table 4) in one or two individuals per week 
is emphasized. 
Table 4 – Proportion of participants whose pelvic region was ir-
radiated by occurrence and degree of radiodermatitis in each 




W1 W2 W3 W4 W5
n 31 31 31 28 26
0 No change 29 28 27 21 20
1 Faint or dull erythema 1 1 2 4 5
1.5 Bright erythema 0 0 1 2 0
2
Dry desquamation 
with or without 
erythema
0 0 0 0 0
2.5
Small to moderate 
amount of moist 
desquamation
1 2 1 1 1
Proportion of patients 





















Figure 1 presents the proportion of patients who devel-
oped some degree of radiodermatitis by week of treatment 
according to the radiated region.











































































1 2 3 4 5
Figure 1 – Proportion and Confidence Interval of patients who presented radiodermatitis in the regions of head and neck, breast, and 
pelvis in five weeks – Brasília, DF, Brazil, 2018.
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DISCUSSION
In this study, the incidence of radiodermatitis among 
patients assisted in the Radiotherapy Outpatient Clinic of 
UNACON/HUB over a 14-month period was estimated. This 
is the first known Brazilian study to estimate the incidence of 
radiodermatitis in cancer patients submitted to radiotherapy. 
A total of 112 patients were followed-up, out of whom 31 had 
head and neck cancer, 50 had breast cancer, and 31 had a cancer 
in the pelvic region (23 prostate, 5 cervix, and 3 endometrium).
The incidence of radiodermatitis ranged from 48% to 
100% and the time for development of radiodermatitis ranged 
from 7 to 18 days. These results are comparable to those found 
in the literature, according to which 90 to 95% of individuals 
submitted to radiotherapy develop some degree of radioder-
matitis(15-16) within a mean 10 to 14 days from the start of the 
treatment(17). In patients whose breast region was irradiated, 
the incidence was 98%, a figure similar to that found in the 
international literature, which varied from 95 to 100%(18-19).
Among patients whose pelvis was irradiated, the propor-
tion of patients who developed some degree of radiodermati-
tis varied from 8% to 26%; the literature does not present any 
data for the incidence of radiodermatitis in this population. 
The smaller incidence in this group may be hypothesized to 
be due to the fact that the areas for irradiation in the pelvic 
region are far from one another (anterior area, right side and 
left side) when compared to the regions of breast and head 
and neck, in which the areas for irradiation may overlap. 
The skin of the pelvic region may be thus more preserved 
regarding the accumulation of dose in the tissue. 
Smoking may be an aggravating factor for the develop-
ment of radiodermatitis since it hinders the process of skin 
healing(12,20). This study’s sample included a high number 
of smokers among patients whose region of head and neck 
was irradiated (81% had been smokers and 6% still were). 
Among patients with breast cancer, four (8%) reported being 
smokers, among whom three presented moist desquamation 
during the treatment. 
Breast size is also related to the development of radio-
dermatitis(6,21). Cutaneous folds may be causes of friction, 
resulting in lesions; this is common in obese people. This may 
also occur in patients with voluminous breasts, particularly 
in the inframammary region(22). In this study, patients with 
voluminous breasts developed more erythema when com-
pared to those with smaller breasts. Also, the two patients 
with the most voluminous breasts of the sample (bra size 54) 
had BMI higher than 30 Kg/m2 (obese) and developed moist 
desquamation in the axillary and inframammary regions. 
The time of occurrence and grade of radiodermatitis may 
be delayed if the care protocol recommended by nurses of the 
service is followed(23-24). The recommendations provided by 
the literature for skin care during radiotherapy are simple and 
involve skin hydration through topical care and water intake, 
wearing appropriate clothing, and sun protection(13,25). This 
study’s patients received information on care of the irradi-
ated region and it is possible that some have thus delayed 
the time of development of radiodermatitis. 
It is extremely important for Brazilian radiotherapy ser-
vices to quantify and characterize radiodermatitis developed 
in cancer patients submitted to radiotherapy in a more sys-
tematic way. The obtention of national data may favor the 
creation of assistance and public policies, considering that 
this radiotoxicity constitutes a limiting factor in treatment 
continuation, possibly interfering with disease prognosis. 
Also, interrupting patient treatment due to radiotoxicity leads 
to postponing the start of radiotherapy for other patients, 
leading to a negative economic impact for the service.
This study’s limitations include the fact that only one 
nurse performed skin assessment, even though the scale is 
well-defined concerning the objective criteria related to the 
signs. However, since the same person assessed the skin of 
all participants, the results were not biased by differences 
between evaluators. 
The sample sizes of each group are not large, which could 
be considered a limitation. However, since this is an estima-
tion study, sample size is reflected in the confidence interval 
size of each estimate. For a higher precision (i.e., smaller 
confidence intervals), bigger samples would be necessary, 
which could be calculated departing from this study. Despite 
this limitation, the results can be generalized to cancer patient 
populations in Brazil with the same inclusion and exclusion 
criteria, similar socioeconomic characteristics, and receiving 
radiation in circumstances which are like those of patients 
in this sample.
CONCLUSION
In this study, the incidence of radiodermatitis was 100% 
among patients whose region of head and neck was irradi-
ated, 98% among those whose breast region was irradiated, 
and 48% among those whose pelvis (cervix, endometrium, 
and prostate) was irradiated.
The need for identifying the incidence of this radio-
toxicity nationwide is emphasized, since it is necessary to 
create and standardize protocols and recommendations for 
proper management of radiodermatitis, specially concerning 
its prevention.
RESUMO
Objetivo: Estimar a incidência e a distribuição de graduação de radiodermatite em pacientes com câncer submetidos à radioterapia 
nas regiões de cabeça e pescoço, mama e pelve. Método: Estudo prospectivo, longitudinal, quantitativo, realizado durante o período de 
15 de março de 2016 a 4 de maio de 2017 com pacientes observados ao longo de cinco semanas de tratamento. O desfecho primário 
foi proporção de radiodermatite grau 1 ou superior em cada semana. Graduação de radiodermatite e tempo médio para a primeira 
ocorrência em cada paciente foram desfechos secundários. Resultados: Participaram 112 pacientes. A incidência de radiodermatite foi 
de 100% entre os que irradiaram a região de cabeça e pescoço, seguida por 98% em mama e 48% na pelve. A graduação de radiodermatite 
variou de acordo com o local da irradiação, com piores graduações na região de cabeça e pescoço, seguida por mama. Nos três grupos, o 
tempo médio para a primeira ocorrência de radiodermatite foi de aproximadamente 11 dias. Conclusão: A incidência de radiodermatite 
foi alta nos grupos estudados, o que reitera a necessidade de se fazer a mesma avaliação em âmbito nacional. Essa avaliação incentivaria 
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a criação e a uniformização de protocolos e recomendações para o manejo adequado da radiodermatite, principalmente no que concerne 
à sua prevenção.
DESCRITORES
Radiodermatite; Neoplasias de Cabeça e Pescoço; Neoplasias da Mama; Neoplasias Pélvicas; Enfermagem Oncológica.
RESUMEN
Objetivo: Estimar la incidencia y la distribución del grado de radiodermatitis en pacientes con cáncer sometidos a radioterapia en 
las regiones de la cabeza y el cuello, la mama y la pelvis. Método: Estudio prospectivo, longitudinal y cuantitativo realizado entre el 
15 de marzo de 2016 y el 4 de mayo de 2017 con pacientes observados durante cinco semanas de tratamiento. El resultado primario 
fue la proporción de radiodermatitis grado 1 o superior cada semana. El grado de radiodermatitis y el tiempo medio de la primera 
aparición en cada paciente fueron resultados secundarios. Resultados: Participaron 112 pacientes. La incidencia de radiodermatitis fue 
del 100% entre los que se irradiaron en la región de la cabeza y el cuello, seguida del 98% en la mama y el 48% en la pelvis. El grado 
de radiodermatitis variaba según el sitio de irradiación, con peores grados en la región de la cabeza y el cuello, seguida de la mama. 
En los tres grupos, el tiempo medio para la primera aparición de radiodermatitis fue de aproximadamente 11 días. Conclusión: La 
incidencia de la radiodermatitis fue elevada en los grupos estudiados, lo que reitera la necesidad de hacer la misma evaluación en todo 
el país. Esta evaluación fomentaría la creación y la uniformización de los protocolos y recomendaciones para el manejo adecuado de la 
radiodermatitis, especialmente en lo que respecta a su prevención.
DESCRIPTORES
Radiodermatitis; Neoplasias de Cabeza y Cuello; Neoplasias de la Mama; Neoplasias Pélvicas; Enfermería Oncológica.
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